TNF and cancer: There was no increase in the risk of new or recurrent cancer with VDZ (HR 1.38, 95% CI: 0.38–1.36) or anti-TNF therapy (HR 1.03, 95% CI: 0.65–1.64) when compared to non-immunosuppressive therapy.